Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 347

1.

Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.

D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M.

Biol Psychiatry. 2012 Nov 1;72(9):785-94. doi: 10.1016/j.biopsych.2012.05.009. Epub 2012 Jun 19.

PMID:
22717030
2.

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS.

Arch Gen Psychiatry. 1994 Mar;51(3):199-214.

PMID:
8122957
3.

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC.

Arch Gen Psychiatry. 2000 Dec;57(12):1139-47.

PMID:
11115327
4.

Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention.

Knott VJ, Millar AM, McIntosh JF, Shah DK, Fisher DJ, Blais CM, Ilivitsky V, Horn E.

Biol Psychol. 2011 Sep;88(1):83-93. doi: 10.1016/j.biopsycho.2011.06.012. Epub 2011 Jul 13.

PMID:
21742012
5.

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH.

Arch Gen Psychiatry. 2000 Mar;57(3):270-6.

PMID:
10711913
6.

Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.

Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB Jr, Suckow RF, Stetson P, Heninger GR, Charney DS.

Psychopharmacology (Berl). 1998 Feb;135(3):213-29.

7.

[Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects].

Micallef J, Tardieu S, Gentile S, Fakra E, Jouve E, Sambuc R, Blin O.

Neurophysiol Clin. 2003 Jun;33(3):138-47. French.

PMID:
12909392
8.

Using ketamine to model semantic deficits in schizophrenia.

Neill E, Rossell SL, McDonald S, Joshua N, Jansen N, Morgan CJ.

J Clin Psychopharmacol. 2011 Dec;31(6):690-7. doi: 10.1097/JCP.0b013e318234ee1e.

PMID:
22020346
9.

Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults.

Lofwall MR, Griffiths RR, Mintzer MZ.

Exp Clin Psychopharmacol. 2006 Nov;14(4):439-49.

PMID:
17115871
10.

Efficacy of a nicotine (4 mg)-containing lozenge on the cognitive impairment of nicotine withdrawal.

Atzori G, Lemmonds CA, Kotler ML, Durcan MJ, Boyle J.

J Clin Psychopharmacol. 2008 Dec;28(6):667-74. doi: 10.1097/JCP.0b013e31818c9bb8.

PMID:
19011436
11.

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.

Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, Macdougall L, Abi-Saab W, D'Souza DC.

Arch Gen Psychiatry. 2005 Sep;62(9):985-94.

PMID:
16143730
12.

Effects of subanesthetic doses of ketamine on sensorimotor information processing in healthy subjects.

Micallef J, Guillermain Y, Tardieu S, Hasbroucq T, Possamaï C, Jouve E, Blin O.

Clin Neuropharmacol. 2002 Mar-Apr;25(2):101-6.

PMID:
11981237
13.

The effects of nicotine on cognition are dependent on baseline performance.

Niemegeers P, Dumont GJ, Quisenaerts C, Morrens M, Boonzaier J, Fransen E, de Bruijn ER, Hulstijn W, Sabbe BG.

Eur Neuropsychopharmacol. 2014 Jul;24(7):1015-23. doi: 10.1016/j.euroneuro.2014.03.011. Epub 2014 Apr 8.

PMID:
24766971
14.

Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.

Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP.

Arch Gen Psychiatry. 2005 Jun;62(6):649-59.

PMID:
15939842
15.

The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers.

Parwani A, Weiler MA, Blaxton TA, Warfel D, Hardin M, Frey K, Lahti AC.

Psychopharmacology (Berl). 2005 Dec;183(3):265-74. Epub 2005 Oct 12.

PMID:
16220331
16.

Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study.

Morgan CJ, Muetzelfeldt L, Curran HV.

Addiction. 2010 Jan;105(1):121-33. doi: 10.1111/j.1360-0443.2009.02761.x. Epub 2009 Nov 17. Erratum in: Addiction. 2010 Apr;105(4):766.

PMID:
19919593
17.

Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder.

Potter AS, Newhouse PA.

Pharmacol Biochem Behav. 2008 Feb;88(4):407-17. Epub 2007 Sep 26.

PMID:
18022679
18.

Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration.

Amitai N, Markou A.

Psychopharmacology (Berl). 2009 Jan;202(1-3):275-86. doi: 10.1007/s00213-008-1246-0. Epub 2008 Jul 11.

19.

Effects of ketamine-induced psychopathological symptoms on continuous overt rhyme fluency.

Nagels A, Kirner-Veselinovic A, Wiese R, Paulus FM, Kircher T, Krach S.

Eur Arch Psychiatry Clin Neurosci. 2012 Aug;262(5):403-14. doi: 10.1007/s00406-011-0281-8. Epub 2011 Dec 22.

PMID:
22189657

Supplemental Content

Support Center